Source link : https://www.newshealth.biz/health-news/cdk-4-6-blocker-prolongs-survival-in-her2-breast-cancer/
SAN ANTONIO — Adding the CDK 4/6 blocker palbociclib to standard endocrine and antihuman epidermal growth factor receptor 2 (HER2) therapies in metastatic hormone receptor (HR)–positive, HER2-positive breast cancer extended patients’ median progression-free survival more than a year, according to the results of the phase 3 PATINA study. This regimen “may represent a new standard […]
Author : News Health
Publish date : 2025-01-09 06:51:21
Copyright for syndicated content belongs to the linked Source.
Categories